Surfactant Protein D as a Potential Biomarker and Therapeutic Target in Ovarian Cancer.
SP-D
biomarker
circulating tumor cells
innate immunity
ovarian cancer
surfactant protein
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
22
03
2019
accepted:
04
06
2019
entrez:
25
7
2019
pubmed:
25
7
2019
medline:
25
7
2019
Statut:
epublish
Résumé
Surfactant protein D (SP-D) is an important innate immune molecule that is involved in clearing pathogens and regulating inflammation at pulmonary as well as extra-pulmonary sites. Recent studies have established the role of SP-D as an innate immune surveillance molecule against lung and pancreatic cancer, but little is known about its involvement in signaling pathways it can potentially activate in ovarian cancer. We focused our study on ovarian cancer by performing bioinformatics analysis (Oncomine) of datasets and survival analysis (Kaplan-Meier plotter), followed by immunohistochemistry using ovarian cancer tissue microarrays. SP-D mRNA was found to be expressed widely in different types of ovarian cancer irrespective of stage or grade. These
Identifiants
pubmed: 31338320
doi: 10.3389/fonc.2019.00542
pmc: PMC6629871
doi:
Types de publication
Journal Article
Langues
eng
Pagination
542Références
J Clin Invest. 2001 Feb;107(4):467-75
pubmed: 11181646
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Biol Chem. 2002 Aug 2;277(31):28127-34
pubmed: 12000755
Clin Exp Metastasis. 2002;19(3):247-58
pubmed: 12067205
Immunol Lett. 2003 May 1;86(3):299-307
pubmed: 12706535
Cell. 2003 Jul 25;114(2):181-90
pubmed: 12887920
J Mol Biol. 2003 Aug 8;331(2):509-23
pubmed: 12888356
Neoplasia. 2004 Jan-Feb;6(1):1-6
pubmed: 15068665
Clin Cancer Res. 2004 May 15;10(10):3291-300
pubmed: 15161682
Mol Immunol. 2006 Mar;43(9):1293-315
pubmed: 16213021
Cancer Res. 2006 Feb 1;66(3):1354-62
pubmed: 16452189
Endocrinology. 2006 May;147(5):2557-66
pubmed: 16469801
Oncol Rep. 2006 Nov;16(5):981-8
pubmed: 17016581
Neoplasia. 2007 Feb;9(2):166-80
pubmed: 17356713
Int J Oncol. 2007 Jul;31(1):181-91
pubmed: 17549420
Int Immunol. 2008 Aug;20(8):993-1007
pubmed: 18628238
Chest. 2008 Sep;134(3):582-588
pubmed: 18779194
Carcinogenesis. 2009 Jan;30(1):114-21
pubmed: 18796737
Gynecol Oncol. 2009 Jan;112(1):185-91
pubmed: 18954898
J Mol Biol. 2009 Dec 11;394(4):776-88
pubmed: 19799916
Anticancer Res. 2010 Sep;30(9):3529-34
pubmed: 20944133
Nat Med. 2011 Jul 03;17(7):860-6
pubmed: 21725296
Methods Mol Biol. 2012;821:105-24
pubmed: 22125063
COPD. 2012 Aug;9(4):409-16
pubmed: 22509983
Front Immunol. 2012 Jun 07;3:131
pubmed: 22701116
Oncogene. 2013 Aug 22;32(34):3923-32
pubmed: 23246968
Methods Mol Biol. 2014;1100:273-90
pubmed: 24218267
PLoS One. 2013 Dec 31;8(12):e85046
pubmed: 24391984
Oncogene. 2015 Feb 12;34(7):838-45
pubmed: 24608429
Expert Rev Proteomics. 2014 Jun;11(3):355-69
pubmed: 24697551
Biochim Biophys Acta. 2015 Jul;1849(7):812-20
pubmed: 25735853
Ann Transl Med. 2015 Mar;3(3):36
pubmed: 25815297
Oncoscience. 2015 Apr 06;2(4):382-94
pubmed: 26097872
Sci Rep. 2015 Jul 30;5:12584
pubmed: 26223541
Immunobiology. 2016 Feb;221(2):310-22
pubmed: 26563748
PLoS One. 2015 Dec 07;10(12):e0143379
pubmed: 26641881
Int J Oncol. 2016 Jul;49(1):133-43
pubmed: 27211906
Am J Respir Crit Care Med. 2017 Dec 15;196(12):1526-1534
pubmed: 28915062
Carcinogenesis. 2018 Mar 8;39(3):407-417
pubmed: 29126163
Front Immunol. 2018 Jun 04;9:1126
pubmed: 29915574
Front Immunol. 2018 Aug 06;9:1748
pubmed: 30127783
Front Immunol. 2018 Aug 15;9:1844
pubmed: 30158928
Int J Mol Med. 2019 Jan;43(1):47-56
pubmed: 30387804
Curr Opin Immunol. 1994 Jun;6(3):407-13
pubmed: 7917108
J Biol Chem. 1998 Apr 17;273(16):9357-60
pubmed: 9545256
Am J Respir Crit Care Med. 1998 Aug;158(2):510-8
pubmed: 9700129
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13618-23
pubmed: 9811849